Neurologist Thomas Brott, M.D., the Eugene and Marcia Applebaum Professor of Neurosciences on Mayo Clinic's Florida campus, has been selected as the recipient of the 2017 Research Achievement Award from the American Heart Association. He received the honor on Sunday, November 12, during the American Heart Association's Scientific Sessions in Anaheim, California. The recognition rewards distinguished lifetime scientific achievement in the field of cardiovascular research.

The American Heart Association Council on Clinical Cardiology presented its James B. Herrick Award for Outstanding Achievement in Clinical Cardiology to Arthur J. Moss, M.D., of the University of Rochester Medical Center, Rochester, N.Y., "in recognition of his wide-ranging scientific achievements elevating understanding of critical aspects of coronary disease, thereby positively impacting cardiology patient care."

The American Heart Association presented its 2017 Research Achievement Award to Thomas G. Brott, M.D., "for his pivotal role in the development of life-saving interventions that have revolutionized treatment of acute ischemic stroke, with enormous consequent benefits dramatically reducing stroke death and disability in the world's population."

Hospitals ranked among the best in cardiology and heart surgery by U.S. News and World Report appear no better at performing percutaneous coronary intervention (PCI), a potentially life-saving heart procedure, than unranked hospitals, according to preliminary research presented at the American Heart Association's Scientific Sessions 2017, a premier global exchange of the latest advances in cardiovascular science for researchers and clinicians.

The U.S. Food and Drug Administration expanded the approval of Zelboraf (vemurafenib) to include the treatment of certain adult patients with Erdheim-Chester Disease (ECD), a rare cancer of the blood. Zelboraf is indicated to treat patients whose cancer cells have a specific genetic mutation known as BRAF V600. This is the first FDA-approved treatment for ECD.

Approximately 3.4 million Americans and over 60 million people worldwide are living with epilepsy, a condition marked by recurrent seizures. "Epilepsy is one of the most common neurologic illnesses that exist today and is a huge burden on quality of life," says Dr. William Tatum, neurologist at Mayo Clinic's campus in Jacksonville, Florida.